Unlock instant, AI-driven research and patent intelligence for your innovation.

C6orf167 peptides and vaccines containing the same

A polynucleotide, antigen technology, applied in the field of cancer treatment, biological science, can solve the problem of unproven cancer diagnosis and/or treatment

Inactive Publication Date: 2015-04-15
ONCOTHERAPY SCI INC
View PDF29 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it has not been proven useful in the diagnosis and / or treatment of cancer

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • C6orf167 peptides and vaccines containing the same
  • C6orf167 peptides and vaccines containing the same
  • C6orf167 peptides and vaccines containing the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0399] Cell Lines and Clinical Samples

[0400] 23 human lung cancer cell lines including 19 NSCLC (A427, A549, NCI-H1373, LC319, PC-14, PC-3, PC-9, NCI-H1666, NCI-H1781, NCI-H647, NCI-H226, NCI -H1703, NCI-H520, LU61, RERF-LC-AI, SK-MES-1, EBC-1, LX1, and NCI-H2170) and 4 kinds of SCLC (DMS114, DMS273, SBC-3, and SBC-5) . Human esophageal cancer cell lines included 9 squamous cell carcinomas (SCC: TE1, TE2, TE3, TE4, TE5, TE6, TE8, TE9, and TE10) and 1 adenocarcinoma (ADC: TE7). All cells were cultured in monolayer in appropriate medium supplemented with 10% fetal calf serum (FCS) and maintained at 37°C with 5% CO 2 in the humid air.

[0401] Human small airway epithelial cells, SAEC (Cambrex Bio Science Inc., East Rutherford, NJ) were also included in the set of cells used. Primary NSCLC samples were previously obtained with informed consent.

[0402] The A24 lymphoblastoid cell line (A24LCL) was established by transforming Epstein-Barr virus into HLA-A24 positive human...

Embodiment 2

[0450] cell line

[0451] T2, HLA-A*0201 positive B lymphoblastoid cell line and COS7, African green monkey kidney cell line were purchased from ATCC.

[0452] Selection of C6orf167-derived peptide candidates

[0453] C6orf167-derived 9- and 10-mer peptides that bind HLA-A*0201 molecules were predicted using the binding prediction software "BIMAS" (www-bimas.cit.nih.gov / molbio / hla_bind) (Parker et al. (J Immunol 1994, 152(1):163-75), Kuzushima et al. (Blood 2001, 98(6):1872-81)). The peptides were synthesized by Biosynthesis (Lewisville, Texas) following standard solid phase synthesis and purified by reverse phase high performance liquid chromatography (HPLC). The purity (>90%) and identity of the peptides were determined by analytical HPLC and mass spectrometry analysis, respectively. Peptides were dissolved in dimethyl sulfoxide at 20 mg / ml and stored at -80°C.

[0454] In vitro CTL induction

[0455]Monocyte-derived dendritic cells (DC) were used as antigen prese...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Peptide vaccines against cancer are described herein. In particular, epitope peptides derived from the C6orf167 gene that elicit CTLs are provided. Antigen-presenting cells and isolated CTLs that target such peptides, as well as methods for inducing the antigen-presenting cell, or CTL are also provided. The present invention further provides pharmaceutical compositions containing peptides derived from C6orf167 or polynucleotides encoding the polypeptides as active ingredients. Furthermore, the present invention provides methods for the treatment and / or prophylaxis of (i.e., preventing) cancers (tumors), and / or the prevention of postoperative recurrence thereof, as well as methods for inducing CTLs, methods for inducing anti-tumor immunity, using the peptides derived from C6orf167, polynucleotides encoding the peptides, or antigen-presenting cells presenting the peptides, or the pharmaceutical compositions of the present invention.

Description

technical field [0001] This application claims the benefit of US Provisional Application No. 61 / 211,700, filed April 1, 2009, the entire contents of which are hereby incorporated by reference. [0002] The present invention relates to the field of biological sciences, more specifically to the field of cancer treatment. In particular, the present invention relates to novel peptides effective as cancer vaccines, drugs for treating and preventing tumors, and methods for diagnosing tumors. Background technique [0003] It has been demonstrated that CD8-positive cytotoxic T lymphocytes (CTLs) recognize epitope peptides derived from tumor-associated antigens (TAAs) found on major histocompatibility complex (MHC) class I molecules and then kill tumor cells . Since the discovery of the first example of TAA, the melanoma antigen (MAGE) family, many other TAAs have been discovered mainly by immunological means (NPL 1 / Boon T, Int JCancer 1993 May 8, 54(2) : 177-80; NPL 2 / Boon T & va...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07K7/06A61K39/00A61P35/00C07K14/82C07K16/32C12N15/09C12Q1/04C12Q1/68G01N33/50G01N33/574
CPCC12Q2600/112A61K39/0011G01N33/57407C12Q1/6886A61P35/00A61P35/02A61P37/04
Inventor 中村佑辅醍醐弥太郎角田卓也大泽龙司吉村祥子渡边朝久
Owner ONCOTHERAPY SCI INC